Quick Facts: What Sulfaprim Treats

• Aims to manage specific bacterial infections
• Used to address discomfort caused by urinary tract infections
• Supports the treatment of acute exacerbations of chronic bronchitis
• Provides an option for addressing traveler's diarrhea
• May be used to help prevent Pneumocystis pneumonia

---

Sulfaprim (also known as co-trimoxazole) is a combination medication approved to manage specific types of bacterial infections. It is a prescription treatment that may be used to address discomfort and resolve symptoms associated with urinary tract infections (UTIs) when caused by susceptible organisms. The medication may also be utilized to support the treatment of acute middle ear infections in pediatric patients, based on a physician’s determination.

For adults, Sulfaprim is an available option for addressing acute exacerbations of chronic bronchitis due to certain susceptible bacterial strains. Additionally, it may be prescribed for the treatment of shigellosis and traveler’s diarrhea when caused by enterotoxigenic E. coli. Sulfaprim is also routinely used for the treatment and prophylaxis of Pneumocystis jirovecii pneumonia (PJP) in individuals who are immunocompromised. These therapeutic domains represent key uses for the drug.

Eligibility Profile: Who Can and Cannot Use Sulfaprim (Trimethoprim/Sulfamethoxazole)

Official regulatory guidelines define specific patient populations and conditions that restrict or prohibit the use of Sulfaprim. This profile is based on absolute contraindications and necessary conditional use requirements.

---

Absolute Contraindications (Must Not Use)

Population/Condition	Restriction Basis
Hypersensitivity	Known allergy to trimethoprim or sulfonamides.
Infants	Under two months of age (risk of kernicterus).
Pregnancy/Lactation	Prohibited in pregnant and nursing mothers (risk of kernicterus).
Organ/Blood Issues	Marked hepatic damage, documented megaloblastic anemia, or severe renal insufficiency if monitoring is not possible.
History	Drug-induced immune thrombocytopenia caused by sulfonamides/trimethoprim.

---

Restricted or Conditional Use

Use of Sulfaprim requires special caution or dosage adjustments in patients with impaired renal function, G-6-PD deficiency, a predisposition to folate deficiency (such as older adults), or underlying severe allergy or asthma. The safety of repeated use has not been established in pediatric patients under two years of age.

Interactions with other medicines and products

Sulfaprim (Sulfamethoxazole/Trimethoprim) may interact with numerous medicines through two primary mechanisms: the inhibition of certain liver enzymes and kidney transporters, and its effect on folate metabolism.

Contraindicated Combination

Concomitant use of Sulfaprim with dofetilide (an anti-arrhythmic medicine) is contraindicated due to the potential for significantly increased dofetilide levels, which can lead to serious heart rhythm abnormalities.

Clinically Significant Interactions

• Anticoagulants: Sulfaprim increases the activity of warfarin, requiring frequent monitoring of blood clotting time and possible dosage reduction of the anticoagulant.
• Oral Hypoglycemics: The medicine can increase the effects of certain drugs used to lower blood sugar, such as sulfonylureas (e.g., glipizide, glyburide) and repaglinide, potentially causing low blood sugar (hypoglycemia).
• Phenytoin: Sulfaprim elevates the blood concentration of the anti-epileptic medicine phenytoin, requiring careful monitoring of phenytoin levels and dosage adjustment.
• Methotrexate: Combining with methotrexate (a folate antagonist) increases the risk of bone marrow suppression and related toxicities, requiring close patient monitoring and potential supplementation.
• Immunosuppressants: When co-administered with cyclosporine, there is an increased risk of kidney toxicity, particularly in renal transplant recipients.
• ACE Inhibitors: Concomitant use with ACE inhibitors (e.g., lisinopril) or potassium-sparing diuretics increases the risk of elevated serum potassium (hyperkalemia).
• Digoxin: Sulfaprim may raise the blood concentration of digoxin, especially in elderly patients, necessitating monitoring of digoxin levels.

Sulfaprim is a fixed-dose combination composed of sulfamethoxazole and trimethoprim, which target the microbial folate synthesis pathway. Both components are enzyme inhibitors that act on successive molecular steps, leading to a synergistic effect primarily within susceptible microbial cells.

Sulfamethoxazole is a competitive antagonist of para-aminobenzoic acid (PABA) at the active site of the enzyme dihydropteroate synthase. This interaction blocks the condensation reaction, inhibiting the formation of dihydrofolic acid (DHF).

Trimethoprim is a selective inhibitor of the enzyme dihydrofolate reductase (DHFR). This enzyme is responsible for the reduction of DHF to the biologically active tetrahydrofolic acid (THF).

The dual blockade of these two consecutive enzymatic reactions in the intracellular pathway prevents the essential synthesis of THF. Downstream, the depletion of THF cofactors halts the synthesis of purines and thymidylate, which are necessary precursors for nucleic acid (DNA and RNA) and protein production. This system-level physiological consequence modulates microbial cell proliferation.

Official Administration Guidelines

The use of Sulfaprim (Co-trimoxazole) is governed by established instructions regarding administration route, dosing, frequency, and patient-specific adjustments.

Administration Details

Parameter	Requirement
Approved Routes	Oral (Tablet, Suspension) and Intravenous (IV Infusion).
Standard Adult Dose	160 mg Trimethoprim / 800 mg Sulfamethoxazole (DS equivalent) every 12 hours.
Timing & Intake	May be taken with or after food. Oral forms must be consumed with a full glass of water.
IV Procedure	Must be diluted in 5% Dextrose in Water (D5W) and administered as a slow infusion over 60 to 90 minutes.
Course Duration	Varies by infection: 5 days for shigellosis; 10-14 days for acute UTI/bronchitis; 14-21 days for PJP treatment.

Population-Specific Rules

Prescribing information indicates dosage adjustments for specific patient populations:

• Pediatric Use: Use is restricted to patients two months of age and older, with dosing calculated based on body weight or body surface area.
• Renal Impairment: Patients with moderate renal function impairment (Creatinine Clearance 15-30 mL/min) must receive half the standard dosage. The medicine is not recommended for use in patients with severe renal insufficiency (CrCl < 15 mL/min), due to how the body clears the medication.

If a dose is forgotten, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients must not take a double dose to compensate for a forgotten dose.

Research Evidence / Overview of Studies for Sulfaprim

---

Evidence for Use in Urinary Tract Infections (UTIs)

Sulfaprim was studied for its use in treating urinary tract infections, a condition characterized by fluctuating or episodic manifestations. Research primarily includes randomized controlled trials (RCTs) and various retrospective studies. These trials focused on outcomes such as the measurement of bacterial counts in the urine (clearance) and patient-reported outcomes describing perceived discomfort.

Findings describe patterns observed in the studies where measurements related to documented bacterial count changes and patient-reported discomfort levels were documented. However, findings were mixed depending on the specific infection type, comparison group, and local bacterial resistance patterns. Long-term effects regarding the rate at which UTIs may return after the study period are not fully established.

---

Evidence for Use in Respiratory and Ear Infections

Research has also examined Sulfaprim in conditions involving periods of heightened symptoms related to the respiratory tract and the middle ear. Trials were evaluated in individuals experiencing acute middle ear infections and acute flare-ups of chronic bronchitis. These studies explored outcomes reflecting daily functioning and outcomes describing episodic or acute changes in symptoms.

Studies report how symptoms evolved in the observed populations over short follow-up periods, documenting measured changes in symptoms. However, evidence is limited when considering the full spectrum of causes for these common infections. Follow-up durations were limited primarily to the short course of treatment, and long-term effects regarding the recurrence of these conditions are not fully established.

---

Evidence in Special Populations

Evidence is limited or requires careful interpretation when considering the drug’s use in certain special populations. Studies explored the use in children; however, data for certain groups remain insufficient, especially infants under two months of age, where use may be associated with specific concerns related to bilirubin and jaundice, which has resulted in limited data for this group.

Findings were mixed or certainty remains low when evaluating individuals with significant underlying comorbid conditions that affect the kidneys or liver, as studies in these populations are often limited. Research is ongoing to fully characterize the patterns of drug exposure in these specific patient groups.

Common questions about Sulfaprim (FAQ)

---

Q: Can I drink alcohol while taking Sulfaprim?

A: Official drug information warns that taking this medicine alongside alcohol has the potential to cause a reaction similar to the effect of disulfiram. This interaction may result in symptoms such as flushing, rapid heartbeat, nausea, and vomiting.

---

Q: How long does it take for Sulfaprim to start working?

A: According to the official product information, the active components typically reach their highest concentration in the blood within one to four hours after taking an oral dose. The drug's official information indicates that stable drug levels, referred to as steady-state, are typically reached after approximately three days of regular administration.

---

Q: Does this medicine contain any common allergens like gluten or lactose?

A: The official product labeling for Sulfaprim lists the full contents, including all inactive ingredients (excipients). Patients are advised to check the specific product's package insert or consult a pharmacist to verify the exact presence or absence of substances like gluten or lactose in their prescribed form.

---

Q: Is Sulfaprim a penicillin-class antibiotic?

A: No, Sulfaprim is not a penicillin-class antibiotic. It is classified as a potentiated sulfonamide antibiotic. This means the medication is a combination of a sulfonamide drug and trimethoprim, working together as an antimicrobial agent.

---

Q: Is Sulfaprim effective for ear infections (Otitis Media)?

A: Official regulatory documents indicate that the treatment of acute otitis media (middle ear infection) is an approved use for this medicine in children. Its use is based on the treating physician’s assessment of whether the medicine is appropriate for the specific patient.

---

Q: How long does a course of treatment usually last?

A: The required duration of treatment can vary and is determined by the specific infection being addressed. Prescribing information provides examples of treatment courses ranging from as short as 5 days up to 21 days for certain infections.

---

Q: What is the specific dosage for a standard adult?

A: The standard adult dosage, such as for urinary tract infections, is defined by the component amounts: mathbf160 mg of trimethoprim and mathbf800 mg of sulfamethoxazole (DS equivalent). Consult the prescribing information for administration frequency.

---

Q: Can I take this medicine if I have diabetes?

A: Regulatory documents indicate that Sulfaprim has documented interactions with certain oral medications used to manage blood sugar in diabetes. Patients taking these blood sugar medications may require close monitoring.

Storage and Disposal of Sulfaprim (Sulfamethoxazole and Trimethoprim)

Storage Requirements

Sulfaprim tablets, oral suspension, and injection concentrate must be stored at controlled room temperature ranging from 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The medicine must be kept in its original container with the lid tightly closed. The oral suspension specifically requires protection from light.

Handling and Stability

The injection solution must not be refrigerated or frozen. The oral suspension has a limited stability period (e.g., 60 days) after dispensing. All forms of the product must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Sulfaprim should be disposed of through a drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance (e.g., coffee grounds) and seal it for disposal in the household trash. The medicine must not be flushed down the toilet or poured into a drain.